Wen-Juan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen-Juan Liu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jian Xu
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100050, Beijing, China
2 shared publicationsBin-Li Zuo
Shandong Provincial Key Laboratory of Radiation Oncology; Shandong Cancer Hospital and Institute; Jinan China
1 shared publicationJia-Lin Wang
Shandong Cancer Hospital and Institute, 250117, Jinan, China
1 shared publicationJun Zhou
University of South Carolina, Computer Science and Engineering Department, Columbia, SC, USA
1 shared publicationLiang Li
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100050, Beijing, China
1 shared publicationQing-Fang Miao
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100050, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 16 July 2018
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 39 (11) , 1777-1786
EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis
Defensins play an essential role in innate immunity. In this study, a novel recombinant β-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting β-defensin consists of an EGF-derived oligopeptide (Ec), a β-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the “scaffold” for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8 ± 0.55, 11.9 ± 0.51, and 5.19 ± 1.21 μmol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10 mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting β-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of β-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.
- 16 July 2018
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 39 (11) , 1777-1786
Open AccessEGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis
Defensins play an essential role in innate immunity. In this study, a novel recombinant β-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting β-defensin consists of an EGF-derived oligopeptide (Ec), a β-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the “scaffold” for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8 ± 0.55, 11.9 ± 0.51, and 5.19 ± 1.21 μmol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10 mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting β-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of β-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.
- Open Access
- 22 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (4) , 5459-5472
Targeted drugs for systemic therapy of lung cancer with brain metastases
Targeted drugs for systemic therapy of lung cancer with brain metastases Targeted drugs for systemic therapy of lung cancer with brain metastases
- 22 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (4) , 5459-5472
Open AccessTargeted drugs for systemic therapy of lung cancer with brain metastases
Targeted drugs for systemic therapy of lung cancer with brain metastases Targeted drugs for systemic therapy of lung cancer with brain metastases
- Open Access
- 1 June 2017
- Published by Wiley in Precision Radiation Oncology
- Vol. 1 (2) , 64-69
Construction of an Ec-LDP-D5 fusion protein that targets human epidermal growth factor receptor and its anti-pancreatic cancer activity
- 1 June 2017
- Published by Wiley in Precision Radiation Oncology
- Vol. 1 (2) , 64-69
Open AccessConstruction of an Ec-LDP-D5 fusion protein that targets human epidermal growth factor receptor and its anti-pancreatic cancer activity